<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189239</url>
  </required_header>
  <id_info>
    <org_study_id>Ze 185-4-2014-02</org_study_id>
    <nct_id>NCT02189239</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress</brief_title>
  <official_title>A Phase IV, Randomised, Placebo Controlled Study to Investigate the Effects of Zeller Entspannung Film Coated Tablets on Cortisol Responses in Healthy Volunteers With Acute Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Zeller Soehne AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max Zeller Soehne AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the STRESS trial is to investigate in a mode of action setting the effect of&#xD;
      Zeller Entspannung film coated tablets on saliva cortisol response versus Placebo after acute&#xD;
      stress in healthy male volunteers. In addition, data on safety and tolerability of Zeller&#xD;
      Entspannung will be obtained.&#xD;
&#xD;
      A third arm including no treatment is tested as well. Approximately 72 healthy volunteers&#xD;
      will be included into this randomized, double blind study. Study duration will be 7 days,&#xD;
      study medication intake will be over 4 days: participants will take the medication one tablet&#xD;
      three times a day (morning, midday, evening) the first 3 days, whereas on day 4 only two&#xD;
      tablets will be taken (morning and midday).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to demonstrate in healthy male volunteers that Zeller Entspannung reduces overall saliva cortisol level (AUCg) after acute stress compared with a placebo.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>The Primary Condition Studied for This Trial is Acute Stress</condition>
  <arm_group>
    <arm_group_label>Zeller Entspannung film coated tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No medication intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zeller Entspannung film coated tablet</intervention_name>
    <arm_group_label>Zeller Entspannung film coated tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Treatment</intervention_name>
    <arm_group_label>No Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age:18 - 45 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Male gender&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic somatic or psychiatric disorder&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Any clinically relevant hepatic disorder&#xD;
&#xD;
          -  Any clinically relevant renal disorder&#xD;
&#xD;
          -  Any clinically relevant cardiac disorder&#xD;
&#xD;
          -  Any clinically relevant respiratory disease (e.g. Asthma)&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Any abnormal lab values suggesting diseases from exclusion criteria&#xD;
&#xD;
          -  Known allergies to trial medication and excipients&#xD;
&#xD;
          -  Alcohol or other drug abuse (e.g. cannabis)&#xD;
&#xD;
          -  Concomitant participation in another clinical trial or &lt;4 weeks ago&#xD;
&#xD;
          -  Participation in any psychotherapy&#xD;
&#xD;
          -  Already participated in a TSST&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phase I Research Unit, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 10, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2014</study_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

